Vaccine Safety Officers are dedicated professionals responsible for monitoring and ensuring the safety of vaccines throughout their lifecycle. They systematically collect and analyze data on adverse events following immunization (AEFI) to identify any potential safety concerns. Working closely with healthcare providers, regulatory authorities, and manufacturers, they investigate safety signals and recommend actions to mitigate risks. Their vigilant work helps maintain public trust by ensuring vaccines remain safe and effective.
Vaccine Safety Officers develop and implement safety protocols, provide training for healthcare workers on vaccine safety practices, and communicate vital information about vaccine risks and benefits to the public. They continuously review clinical trial data and post-marketing surveillance findings to update safety profiles. Their contributions are essential for regulatory compliance and support the ongoing success of immunization programs worldwide, ultimately protecting communities from vaccine-preventable diseases. During public health emergencies, these officers play a critical role in rapidly assessing vaccine safety and addressing public concerns. Their expertise helps shape policy decisions and promotes transparent communication to foster confidence in vaccination efforts. By collaborating internationally, they help harmonize vaccine safety standards across countries. Their proactive approach is key to identifying potential safety issues before they become widespread, ensuring timely interventions and safeguarding public health.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey